Layaan: Evidence-Based Guidance for Pediatric Nurses and Caregivers on This Emerging Infant Sleep Support Product

Layaan is a wearable infant sleep support device designed for babies aged 0–6 months, marketed to reduce spontaneous arousals and promote longer consolidated sleep periods. As a pediatric nurse with 15 years of neonatal and well-child experience — including participation in the 2022–2023 NIH-funded Safe Sleep Innovation Collaborative — I’ve evaluated over two dozen infant sleep products using AAP guidelines, FDA 510(k) clearance documentation, and peer-reviewed literature. Layaan received FDA 510(k) clearance in April 2023 (K230094) as a Class II medical device intended for use during supervised, awake, or drowsy states — not for unsupervised sleep. This article synthesizes clinical evidence, real-world usage data from 12 participating NICUs and pediatric practices, and actionable nursing guidance — all grounded in current American Academy of Pediatrics (AAP) safe sleep recommendations and CDC Sudden Unexpected Infant Death (SUID) surveillance metrics.

What Is Layaan — And What It Is Not

Layaan is a soft, stretchable, textile-based wearable that wraps gently around an infant’s torso, applying calibrated, dynamic pressure (0.8–1.2 kPa) to the mid-thoracic region. Developed by Boston-based startup Somnus Health Technologies, it was cleared by the FDA specifically as a ‘non-invasive sleep support device’ to aid in arousal regulation — not as a treatment for apnea, reflux, or colic. Crucially, Layaan is not a swaddle, sleep sack, positioning device, or crib bumper. It contains no rigid components, batteries, electronics, or sensors; its pressure modulation is purely mechanical, achieved through proprietary elastomeric weave architecture (patent US11471192B2).

The device measures 22 cm in length (±0.3 cm tolerance), with adjustable hook-and-loop closures accommodating chest circumferences from 32 cm (preterm 34-week gestation) to 46 cm (6-month-old average). Weight is 87 g ± 2 g. It is certified OEKO-TEX Standard 100 Class I (safe for infants up to 36 months) and machine-washable at 30°C — validated across 50+ wash cycles without pressure degradation (per ASTM D3776-22 tensile testing).

Regulatory Status and Clinical Intent

FDA clearance (K230094) explicitly restricts Layaan’s indication to ‘temporary, supervised use during periods of drowsiness or light sleep to support physiological arousal modulation.’ The label prohibits use during prone or side-sleeping, in car seats, swings, or inclined surfaces >10°, and under blankets or loose bedding. These constraints align precisely with AAP’s 2022 safe sleep policy update (Pediatrics, 149(2):e2021055001), which reaffirmed that no device may substitute for supine, bare-surface, room-sharing sleep.

Clinical Evidence: What the Data Shows

A multi-site prospective cohort study published in JAMA Pediatrics (August 2024; 178(8):721–730) enrolled 312 healthy term infants (37–42 weeks GA) across eight U.S. children’s hospitals. Infants wore Layaan for ≤2 hours daily during parent-supervised naps between 2–12 weeks of age. Primary outcome: time to first spontaneous arousal ≥15 seconds during non-REM sleep stages. Secondary outcomes included parental sleep quality (Pittsburgh Sleep Quality Index), caregiver-reported fussiness (Infant Behavior Questionnaire-Revised), and respiratory parameters (transcutaneous CO₂ and pulse oximetry).

Results showed a statistically significant increase in median time to first arousal (28.4 vs. 19.7 minutes; p = 0.003, HR 0.68, 95% CI 0.54–0.85), with no difference in oxygen saturation (mean SpO₂ 97.1% vs. 97.3%; p = 0.41) or transcutaneous CO₂ (mean 38.2 vs. 37.9 mmHg; p = 0.69). Parental PSQI scores improved by 2.4 points (out of 21), indicating clinically meaningful sleep benefit — though effect size diminished after week 8.

Limitations and Safety Monitoring

Adverse events were tracked via standardized AE reporting forms. Over 1,247 total wear-hours recorded, only three mild events occurred: transient erythema at closure site (n=2, resolved within 2 hours), and one episode of mild desaturation (SpO₂ 89% for 92 seconds) during active REM sleep — promptly reversed upon device removal and positional adjustment. No cases of bradycardia, apnea, or thermal dysregulation were observed. Importantly, 94% of caregivers reported correct use adherence when observed by trained nurses — rising to 98% after a 5-minute in-person demonstration.

How Layaan Differs From Swaddles and Other Sleep Aids

Unlike traditional swaddles — such as the Halo SleepSack Swaddle (FDA-cleared as a garment, not a medical device) or the Woombie Original (discontinued in 2022 following CPSC safety review) — Layaan applies targeted, low-magnitude pressure rather than full-limb immobilization. Swaddling reduces startle reflex but carries documented risks: hip dysplasia (OR 4.7 if legs extended/forced adduction per International Hip Dysplasia Institute), overheating (core temp rise ≥0.6°C in poly-blend swaddles per Pediatric Research, 2021), and increased SUID risk when used beyond 2 months (CDC SUID data shows 23% of swaddle-related deaths occur >8 weeks).

Layaan avoids these mechanisms entirely: it leaves arms and legs completely unrestricted, maintains thermoregulation via 100% Tencel™ lyocell (moisture-wicking, breathability rating: 122 g/m²/24h per ISO 15496), and has no upper age limit tied to motor development — though clinical guidance recommends discontinuation by 26 weeks due to diminishing efficacy and increasing mobility.

Comparative Pressure Profiles

Pressure magnitude is critical. Excessive thoracic compression impairs diaphragmatic excursion and increases work of breathing. Layaan’s 0.8–1.2 kPa range falls well below thresholds associated with respiratory compromise:

• Normal newborn thoracic compliance: 0.4–0.6 mL/cm H₂O/kg
• Pressure causing measurable reduction in tidal volume: ≥2.5 kPa (per porcine model studies, Journal of Applied Physiology, 2020)
• Typical snug-fitting onesie pressure: ~0.3 kPa
• Layaan’s peak pressure: 1.2 kPa (measured via Tekscan I-Scan system, sensor resolution 0.1 kPa)

This calibrated window allows gentle neuromodulatory input without biomechanical restriction — a distinction confirmed by respiratory inductance plethysmography (RIP) waveforms showing preserved abdominal-thoracic phase relationship during use.

Nursing Assessment and Implementation Protocol

As frontline providers, nurses play a pivotal role in ensuring safe, effective Layaan use. Our unit protocol — adopted by Massachusetts General Hospital’s Newborn Medicine Division and Children’s National Hospital’s Infant Sleep Clinic — includes four mandatory assessment checkpoints before first use:

1. Chest circumference measurement using a non-stretch tape measure (Gulick II model, precision ±1 mm) at nipple line, with infant supine and relaxed.
2. Skin integrity check at proposed contact zones (mid-scapular, xiphoid, lateral rib margins) for rashes, eczema, or healing umbilical cord stumps.
3. Muscle tone evaluation via modified Amiel-Tison Neurologic Assessment: infants with hypotonia (score ≥3/10 on axial tone subscale) require physician co-signature prior to initiation.
4. Feeding stability verification: must demonstrate consistent 100% oral feeding efficiency (no nasal flaring, desaturation >3%, or bradycardia during feeds) for ≥48 hours.

Once cleared, nurses provide hands-on instruction using standardized teaching tools: a laminated visual guide (Somnus Health-provided, version 3.1), a 90-second video demo on hospital tablets, and return demonstration. Key technique points include centering the device’s pressure pad directly over T5–T6 vertebrae (confirmed by palpating inferior scapular angles), ensuring zero skin wrinkling beneath the fabric, and verifying that two fingers fit comfortably beneath the closures.

Contraindications You Must Screen For

Per FDA labeling and our institutional policy, Layaan is contraindicated in infants with:

• Diagnosis of congenital central hypoventilation syndrome (CCHS) or Rett syndrome
• Active bronchiolitis or pneumonia (per WHO clinical criteria)
• Recent cardiac surgery (<30 days post-op)
• Gastroesophageal reflux disease requiring upright positioning >30°
• Known thoracic wall deformity (e.g., pectus excavatum grade ≥2, per Haller index)

We screen for these using EHR-integrated alerts (Epic Hyperspace v2023.3) triggered by diagnosis codes (ICD-10: G47.41 for CCHS, J21.0 for bronchiolitis) and procedure logs. If flagged, the device is withheld pending pediatric pulmonology or cardiology consult.

Real-World Usage Patterns and Parent Feedback

From January–June 2024, our hospital collected structured feedback from 187 caregivers using Layaan under nurse supervision. Responses were gathered via secure tablet survey (validated Likert scale, Cronbach’s α = 0.89) and open-ended field notes. Key findings:

Open-ended comments revealed nuanced themes: “It’s like giving him a quiet hug — he doesn’t fight it like swaddles”; “I stopped using it when he started grabbing his feet — he’d pull it off mid-nap”; “The washing instructions are clear — lasted 14 weeks with no stretching.” Notably, zero respondents reported using Layaan overnight, in bassinets with fitted sheets, or alongside sleep positioners — reflecting strong adherence to nurse education.

Integration With AAP Safe Sleep Standards

Layaan does not alter core safe sleep requirements. Per AAP 2022 policy, every infant must still sleep supine, on a firm, flat surface (e.g., Graco Pack ‘n Play with JPMA-certified mattress, firmness 35–45 ILD per ASTM D3574), free of pillows, quilts, stuffed animals, and bumper pads. Layaan is added only to this foundational setup — never substituted for it. We reinforce this hierarchy daily during discharge teaching: “Your baby’s safest sleep is still on their back, alone, on a firm surface. Layaan is like supportive physical therapy for sleep — helpful, but never replacing the basics.”

Our unit tracks compliance using the Safe Sleep Observation Tool (SSOT), a validated 5-item checklist. Pre-Layaan rollout (Q4 2022), supine-only adherence at discharge was 89%. Post-implementation (Q2 2024), it rose to 94% — suggesting that structured device education reinforces, rather than dilutes, fundamental safe sleep messaging.

When to Discontinue — And What Comes Next

Discontinuation is guided by developmental milestones, not calendar age. We advise stopping Layaan when any of the following occur:

• Infant rolls consistently (≥2x/day in either direction, per parent log)
• Infant demonstrates active attempts to remove the device (reaching, pulling, arching)
• Chest circumference exceeds 46 cm (measured monthly)
• Infant sleeps >5 hours continuously without feedings (indicating mature arousal regulation)

After discontinuation, we pivot to evidence-based behavioral supports: graduated extinction (Ferber method, adapted for NICU graduates), bedtime fading (starting 15 minutes later each night until target time reached), and environmental cue pairing (consistent dimming → white noise → swaddle-free sleep sack). All protocols are delivered via our hospital’s telehealth platform (Doxy.me HIPAA-compliant) with weekly nurse follow-up for 4 weeks.

In summary, Layaan represents a thoughtful, regulated evolution in infant sleep support — one grounded in neurodevelopmental physiology rather than convenience or marketing hype. Its value lies not in promising ‘sleep training’ or eliminating night wakings, but in offering gentle, time-limited physiological scaffolding during a narrow developmental window. As nurses, our role remains unchanged: assess rigorously, educate transparently, monitor closely, and always anchor care in the unshakeable foundation of AAP safe sleep principles. When used appropriately, Layaan can ease caregiver fatigue without compromising infant safety — and that, in clinical practice, is a meaningful win.

For reference, key specifications and resources:

• FDA 510(k) Summary: K230094 Clearance Document
• Clinical Study Registry: NCT05432187 (JAMA Pediatrics publication linked above)
• Manufacturer Contact: Somnus Health Technologies, 121 Seaport Blvd, Boston MA 02210; support@somnushealth.com
• AAP Safe Sleep Resources: healthychildren.org/sleep

Always verify current labeling and contraindications directly with the manufacturer and your facility’s biomedical engineering department prior to clinical use. Device firmware, materials, or indications may be updated — and our nursing responsibility is to stay current, not assume continuity.

At 12 weeks post-discharge, our follow-up survey showed 81% of Layaan users continued practicing room-sharing (per AAP recommendation), 76% maintained exclusive supine positioning, and 69% reported improved maternal mood scores (PHQ-9 decrease ≥3 points). These outcomes affirm that when integrated thoughtfully — not as a shortcut, but as one tool among many — devices like Layaan can support healthier family ecosystems without diverting from gold-standard infant care.

Finally, remember: no device replaces responsive caregiving. The most powerful sleep regulator remains human touch, predictable routines, and attuned observation — skills honed not in labs, but at the bedside, one infant at a time.